CytomX reports updated Phase I data for CX-072 in solid tumors
CytomX Therapeutics Inc. (NASDAQ:CTMX) reported updated data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as monotherapy and in combination with anti-CTLA-4 mAb Yervoy ipilimumab or BRAF inhibitor Zelboraf vemurafenib to treat metastatic or locally advanced unresectable solid tumors or lymphomas. The data were presented at the American Society of Clinical Oncology meeting in Chicago.
In 20 evaluable patients with advanced solid tumors, IV CX-072 every 14 days as monotherapy led to three partial responses, plus eight cases of stable disease. The responses occurred in patients with thymoma, PD-L1-negative triple-negative breast cancer (TNBC) and cervical cancer. Reductions in target lesions were observed in eight of 19 evaluable patients with measurable disease at baseline...